---
title: "Eli Lilly halts diabetes trial of muscle-sparing drug with Zepbound - Bloomberg news"
description: "Sept 25 (Reuters) -Eli Lilly halts diabetes trial of muscle-sparing drug with Zepbound - Bloomberg news"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258857485.md"
published_at: "2025-09-25T10:40:35.000Z"
---

# Eli Lilly halts diabetes trial of muscle-sparing drug with Zepbound - Bloomberg news

> Sept 25 (Reuters) -Eli Lilly halts diabetes trial of muscle-sparing drug with Zepbound - Bloomberg news

Sept 25 (Reuters) -

-   Eli Lilly halts diabetes trial of muscle-sparing drug with Zepbound - Bloomberg news

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pharma's $370 Billion Bet On America: The ETF Plays For 2026 | In 2025, the U.S. pharmaceutical industry rebounded with a $370 billion investment pledge, driven by tariff threats and  | [Link](https://longbridge.com/en/news/270412308.md) |
| BUZZ-Abivax jumps on media reports of Eli Lilly takeover bid | BUZZ-Abivax jumps on media reports of Eli Lilly takeover bid | [Link](https://longbridge.com/en/news/270467110.md) |
| Short Interest in Schneider Electric SE (OTCMKTS:SBGSY) Drops By 16.8% | Schneider Electric SE (OTCMKTS:SBGSY) experienced a 16.8% decrease in short interest in January, with 197,858 shares sho | [Link](https://longbridge.com/en/news/276071356.md) |
| What to Expect from Palo Alto Networks's Earnings | Palo Alto Networks (NASDAQ:PANW) is set to release its quarterly earnings report on February 17, 2026, with analysts exp | [Link](https://longbridge.com/en/news/276061399.md) |
| 03:00 ETSéptima edición del Concurso S.Pellegrino Young Chef Academy | S.Pellegrino has announced the launch of the seventh edition of the S.Pellegrino Young Chef Academy Competition, aimed a | [Link](https://longbridge.com/en/news/276041621.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.